Connect MM- The Multiple Myeloma Disease Registry
Phase of Trial: Phase IV
Latest Information Update: 25 Jun 2017
At a glance
- Drugs Bortezomib (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 25 Jun 2017 Results assessing impact of post-autologous stem cell transplant maintenance therapy (lenalidomide (LEN)-based maintenance) on survival outcomes in patients with newly diagnosed multiple myeloma (cohort 1,n=432), presented at the 22nd Congress of the European Haematology Association.
- 25 Jun 2017 Results evaluating the maintenance treatment on clinical outcomes and HRU presented at the 22nd Congress of the European Haematology Association.
- 19 Jun 2017 According to a Celgene Corporation media release, data from this trial will be presented at the 22nd European Hematology Association annual meeting 2017.